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AbstrACt
Introduction Cerebral palsy (CP), an umbrella term for 
non-progressive conditions of cerebral origin resulting 
in motor impairments, is collectively the most common 
cause of physical disability in childhood. Cerebral and/
or non-cerebral congenital anomalies are present in 
15%–40% of children with CP. In order to identify effective 
prevention strategies for this substantial proportion of 
CP, a comprehensive understanding of the epidemiology 
of these congenital anomalies is required. International 
collaboration is needed, as previous attempts have 
fallen short due to a lack of power, since the anomalies 
are individually rare and CP comprises many clinical 
descriptions. The aim of this study is to generate new 
knowledge about the aetiologies of CP through a focused 
investigation into the role of congenital anomalies.
Methods and analysis This collaborative, population-
based data linkage study includes nine geographic 
regions (six in Europe, three in Australia) served by both 
congenital anomaly and CP registers. Register data 
for children with CP (both with and without congenital 
anomalies) and children with specific congenital 
anomalies (without CP) born between 1991 and 2009 
will be linked and de-identified within each region. The 
resulting linked data sets will be quality assured, recoded, 
harmonised and then pooled into one data set. Analysis 
of the combined data set will include: frequencies/
proportions of congenital anomalies and outcomes 
(type of CP, severity, impairments); descriptive analyses 
comparing timing of congenital anomaly development 
and brain injury/abnormality responsible for CP; ORs to 
calculate the odds of CP following a specific congenital 
anomaly; and identification of anomalies on causal 
pathways to CP.
Ethics and dissemination Ethics approval for this 
collaborative study, The Comprehensive CA-CP Study, has 
been obtained from the Cerebral Palsy Alliance Human 
Research Ethics Committee (EC00402). Study findings will 
be disseminated at conferences and published in peer-
reviewed journals, and recommendations will be made 
regarding the collection and classification of congenital 
anomaly data by CP registers.
IntroduCtIon 
Cerebral palsy (CP) is an umbrella term for 
non-progressive motor impairment condi-
tions secondary to lesions or malformations 
of the developing brain. The condition is 
also associated with impairments of cogni-
tion, sensation and/or epilepsy.1 Known 
risk factors for this lifelong disability span 
the period prior to conception through to 
2 years of age.1 They include genetic factors, 
multiple births, congenital anomalies, intra-
uterine growth restriction, infection, preterm 
birth and hypoxia ischaemia, as well as events 
in early childhood such as cerebrovascular 
accidents.1 After a relatively stable birth prev-
alence of 2–2.5/1000 live births over the last 
strengths and limitations of this study
 ► We expect this study to be the largest of its kind 
worldwide; it will include data from all regions 
of Europe and Australia served by active popula-
tion-based congenital anomaly and cerebral palsy 
(CP) registers.
 ► The integrity of the collaborative study will be main-
tained by the use of strict definitions of CP and in-
cluded congenital anomalies, as well as flexibility in 
the inclusion of registers in individual analyses.
 ► By obtaining congenital anomaly data from both CP 
and congenital anomaly registers, this study enables 
access to the most comprehensive and highest 
quality description of congenital anomalies.
 ► This study will be the first to report risk of CP for 
individuals with the congenital anomalies most 
strongly associated with CP.
 ► A limitation of the study is the possibility of mi-
gration of children with congenital anomalies out 
of a region, prior to a description of CP at age 4 or 
5 years, which may lead to underestimation of cases 
with both CP and congenital anomalies.
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60 years, the most recent evidence from Europe and 
Australia suggests we are starting to see a decline.1–3 It is 
anticipated that these declines are in children born very 
preterm and those with hypoxic ischaemia at birth where 
neonatal interventions have proven effective.3 
The prevalence of congenital anomalies is estimated at 
approximately 3%–6% of the population,4 5 depending 
on how both congenital anomalies and the denominator 
are defined. Congenital anomalies can occur in any body 
system as an isolated anomaly or as multiple anomalies 
and range from minor to severe or lethal. Recognised 
aetiologies are heterogeneous, and include chromo-
somal and genetic abnormalities, teratogenic exposure, 
micronutrient deficiencies and infectious disease but a 
large proportion have no recognised aetiology, further 
complicating epidemiological studies.6 Congenital anom-
alies can result in lifelong morbidity and disability, and 
are responsible for 276 000 neonatal deaths worldwide 
annually.7
Register-based studies have determined that congen-
ital anomalies occur more frequently in children with CP 
than the general population.8–10 European and Austra-
lian register-based studies have described anomalies in 
15%–40% of children with CP.10 11 The increased risk of 
anomalies exists for those with a presumed pre/perinatal 
brain injury, as well as those with a recognised postneo-
natal cause.12 An increased rate both of cerebral and of 
non-cerebral anomalies, particularly cardiac defects, has 
been described in the CP group.10 12–14 When congenital 
anomalies are observed in children with CP, they are often 
associated with more severe long-term outcomes.8–10 12
Research in this area to date has considered individual 
registers or small linkage studies. Given the relatively rare 
occurrence of CP, and the vast range of possible congen-
ital anomalies, much larger study samples are required 
to generate statistically robust observations. With a larger 
population, research can focus on investigating groups of 
cases with similar anomalies and exploring their aetiology 
and outcomes.
No previous study has been able to determine the risk 
of CP for children born with specific congenital anom-
alies. This is important information both for clinicians 
prognosticating to families and to raise awareness among 
researchers who are working on the prevention of malfor-
mations that they may also prevent some cases of cerebral 
palsy. We seek to redress this gap in our study.
To devise an appropriate and feasible collaboration, 
we distributed a survey to all known CP and congenital 
anomaly registers in Europe and Australia. The survey 
aimed to elucidate inclusion/exclusion criteria, methods 
of data collection and data available at each register and 
to ascertain their interest in participating in this collabo-
ration. The results of the survey have helped to shape the 
scope and design of this study protocol. Of the 47 regis-
ters contacted, 37 responded (79% response rate): 26 
European and 11 Australian. The definitions used for CP 
were consistent; however, inclusion/exclusion criteria for 
congenital anomalies differed. The coding of anomalies 
differed by type of register and geographical region, and 
even within individual registers over time; however, these 
variations can be addressed using conversion codes and a 
computer algorithm. This process identified populations 
served by both a CP register and a congenital anomaly 
register who were willing and able to collaborate from 
four European and two Australian regions; unfortunately, 
one European CP register has since unexpectedly closed 
necessitating withdrawal from the study. Further discus-
sions with non-responders to the survey resulted in an 
additional three regions from Europe and one region 
from Australia joining the study. More than 270 000 live 
births/year occur within these nine regions, and this 
study will therefore consider approximately seven times 
the sample size of the largest previous equivalent study 
(table 1).10 The Comprehensive CA-CP Study will pool 
data from registers in the Surveillance of Cerebral Palsy 
in Europe (SCPE) and in the European Surveillance of 
Congenital Anomalies (EUROCAT) with that from the 
Australian Cerebral Palsy Register (ACPR) and Australian 
congenital anomaly registers.
MEthods And AnAlysIs
Aim and research questions
The aim of The Comprehensive CA-CP Study is to 
generate new knowledge about the aetiologies of CP 
through a focused investigation into the role of congen-
ital anomalies in the mechanisms leading to CP. Our 
research questions are: (a) What is the frequency and 
proportion of children with CP (described by gestational 
age groupings, sex and plurality) that have recognised 
cerebral and/or non-cerebral congenital anomalies?; (b) 
What are the clinical outcomes (including motor type, 
gross motor severity and associated impairments of intel-
lect, vision, hearing, speech and epilepsy) of children with 
CP and specific congenital anomalies, compared with 
children with CP without anomalies?; (c) For infants with 
specific congenital anomalies, what is the associated risk 
of CP?; (d) Can the timing of congenital anomaly devel-
opment and the timing of brain injury be identified and 
compared?; (e) Which anomalies are on a causal path to 
CP? Which of these have opportunities for primary and 
secondary prevention?
design and setting
This data linkage study will consider European and 
Australian total populations of live births. CP and congen-
ital anomaly register data from each participating region 
will be linked and subsequently pooled (table 1). A multi-
disciplinary approach is being used with individual collab-
orators from three register networks (EUROCAT, SCPE, 
ACPR) bringing expertise and experience from the fields 
of epidemiology, paediatrics, neonatology, neurology, 
genetics, public and allied health.
EUROCAT is a European network of population-based 
registries for the epidemiological surveillance of congen-
ital anomalies. The surveillance of congenital anomalies 
 o
n
 26 July 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-022190 on 23 July 2018. Downloaded from 
3Goldsmith S, et al. BMJ Open 2018;8:e022190. doi:10.1136/bmjopen-2018-022190
Open access
serves two main purposes: to facilitate the identification 
of teratogenic (malformation causing) exposures and 
to assess the impact of primary prevention and prenatal 
screening policy and practice at a population level. 
Commencing in 1979, EUROCAT surveys more than 
1.7 million births per year in Europe, involving 43 regis-
tries across 23 countries. The central database includes 
more than 340 000 European cases with major congenital 
anomalies. The contributing registries all use the same 
methods and are based on multiple data sources.
The SCPE network is a collaboration of clinicians 
and researchers working with population-based surveys 
or registers of children with CP and extending across 
Europe, currently with 24 partners in 20 countries. SCPE 
was established in 1998 to monitor trends in CP (the data-
base comprises birth years 1975 onwards), to provide a 
framework for collaborative research, to serve as a basis 
for service planning and to raise standards of assess-
ment and care for children with CP. The collaboration 
is examining variations in clinical practice and access 
to healthcare across Europe and further refining how 
children with CP are described, notably using neonatal 
neuroimaging classification. The participating registers 
use the same definition and classification of CP,15 16 and 
contribute data with the same coding.
The ACPR was established in 2008 and is a collaboration 
between the eight geographically defined CP registers 
that together represent all of Australia.17 It is a research 
database holding deidentified data contributed from 
each register, who share a common minimum data set. 
The ACPR was developed to facilitate the study of the 
distribution, frequency and severity of CP, the causes and 
determinants of CP, the effectiveness of prevention strate-
gies, and to help plan and evaluate services.
Participants
To identify the congenital anomalies that co-occur in chil-
dren with CP and their clinical outcomes (all research 
questions), participants will consist of all children with 
confirmed CP (verified at age 4 or 5 years) or with a 
description of CP after age 2 but without verification in 
the event of death prior to 4 or 5 years of age, both with 
and without congenital anomalies, born between 1991 
and 2009 to mothers residing at birth in a region (or 
Table 1 Participating registers
Geographical 
region
Cerebral palsy 
(CP) register
Congenital anomaly 
register
Live births/
year
Birth years 
available
Total live 
births
Approximate CP 
cases available*
EUROPE†
Funen, Denmark Danish CP Register EUROCAT Malformation 
Registry for Funen, 
Denmark
5000 1991–2007 85 000 179
Grenoble, France RHEOP REMERA 31 300 1991–2007 532 100 1117
Norway The CP Register of 
Norway (CPRN)
Medical Birth Registry of 
Norway (MFR)
60 000 1999–2009 660 000 1386
Portugal Programa Vigilância 
Nacional da Paralisia 
Cerebral aos five anos 
de Idade (PVNPC5A)
RENAC—Registo 
Nacional de Anomalias 
Congénitas
18 000 2001–2009 162 000 340
Western 
Sweden**
The CP Register of 
Western Sweden
Swedish Register of 
Birth Defects
24 000 1991–2009 408 000 857
Croatia Register of Cerebral 
Palsy of Croatia (RCP-
HR)
Zagreb EUROCAT 
Register
7000 2003–2007 35 000 74
AUSTRALIA
South Australia South Australian Birth Defects Register‡ 20 000 1993–2009 340 000 714
Victoria Victorian Cerebral Palsy 
Register
Victorian Congenital 
Anomalies Register
70 000 1993–2009 1 104 389 2048
Western 
Australia
Western Australian Register of Developmental 
Anomalies (WARDA)‡
30 000 1991–2009 570 000 1197
Total 265 300 3 896 489 7 912
*Calculated at 2.1/1000 live births.
†All participating European congenital anomaly registers follow EUROCAT methods.
** Individual case data cannot be contributed to the pooled data set housed in Australia. Tabulated data to be included during data analysis 
phase.
‡Colocated/combined congenital anomalies and CP register.
EUROCAT, European Surveillance of Congenital Anomalies. RHEOP, Registre des Handicaps de l'Enfant et Observatoire 
Perinatal. REMERA, Le Registre des Malformations en Rhône-Alpes.
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if not available, infants born in a region) with a partici-
pating CP and congenital anomaly register in Europe or 
Australia.
Children with suspected CP who died before the age of 
2 years or children with CP where the causal brain injury 
is known to have occurred after the age of 2 years will be 
excluded.
SCPE and the ACPR accept any definition of CP that 
includes the following five key elements:
CP is: (1) an umbrella term for a group of disorders; 
(2) is a condition that is permanent but not unchanging; 
(3) involves a disorder of movement and/or posture and 
of motor function; (4) is due to a non-progressive inter-
ference, lesion or abnormality, and (5) the interference, 
lesion or abnormality that originates in the immature 
brain.16
To ascertain the risk of CP for infants with specific 
congenital anomalies (research question c), participants 
will constitute all live births with a confirmed diagnosis of 
the specific congenital anomaly (box 1), with or without 
CP, born between 1991 and 2009 to mothers residing at 
birth in a region (or if not available, infants born in a 
region) with a participating CP and congenital anomaly 
register in Europe or Australia.
The definition of a congenital anomaly varies widely, 
even between registers within one country.18 We have 
identified that variations exist across registers with 
regards to which anomalies are routinely collected and 
which anomalies are reliably identified by a certain age. 
Some congenital anomalies, such as brain malformations, 
may not be identified in the neonatal period. Because of 
this, registers must accept notifications for at least 1 year 
post birth to be included in these analyses. For anomalies 
readily identifiable in the neonatal period (eg, cleft lip 
and palate), all registers will be included.
In order to identify which anomalies should be consid-
ered in research question c (risk of CP for specific congen-
ital anomalies) in this study, we analysed data from a large 
case–control study in Western Australia incorporating 
data from the statewide CP and congenital anomaly regis-
ters.9 Congenital anomalies strongly associated with CP 
in this population sample were compared with findings 
from two European studies.8 10 Anomalies associated with 
CP across both regions comprise the final list of anoma-
lies to be considered (box 1).
data linkage and harmonisation
Data linkage will take place locally by that region’s CP and 
congenital anomaly registers. Each region will nominate 
their primary and secondary register for the study. Given 
the focus of the study and preliminary planning with 
registers, the primary register will most often be the CP 
register. The linkage will commence with the secondary 
register (likely to be the congenital anomaly register) 
providing a file of all registered congenital anomaly 
cases born alive (1991–2009). The linkage process will be 
specific to each geographic region (eg, personal identifier 
number, birth date, sex and/or delivery place), according 
to the data held by each register. The corresponding 
CP register will check which of these children are also 
known to them. Each register will then add relevant data 
for identified cases. Alternate methods of linkage will be 
used for those regions where (1) an internal linkage of 
cases is feasible as the CP and congenital anomaly regis-
ters are colocated within the same register (two regions), 
or (2) an independent data linkage service is used to 
link data from the two registers (one region). Finally, the 
linked file with identifying information replaced with a 
box 1 Congenital anomalies to be studied in research 
question c
Congenital anomaly (International Classification of 
diseases, 10 th revision code and text description)
 ► Q040: Anomaly/agenesis corpus callosum
 ► Q0433: Lissencephaly
 ► Q042: Holoprosencephaly
 ► Q031: Hydrocephalus and Dandy-Walker
 ► Severe congenital heart defects according to European Surveillance 
of Congenital Anomalies definition:
 – Q200: Common arterial trunk
 – Q201: Double outlet right ventricle
 – Q203: Discordant ventriculoarterial connection
 – Q204: Double inlet ventricle
 – Q212: Atrioventricular septal defect
 – Q213: Tetralogy of Fallot
 – Q220: Pulmonary valve atresia
 – Q224: Congenital tricuspid stenosis
 – Q225: Ebstein anomaly
 – Q226: Hypoplastic right heart syndrome
 – Q230: Congenital stenosis of aortic valve
 – Q232: Congenital mitral stenosis
 – Q233: Congenital mitral insufficiency
 – Q234: Hypoplastic left heart syndrome
 – Q251: Coarctation of aorta
 – Q252: Atresia of aorta
 – Q262: Total anomalous pulmonary venous connection
 ► Q203: Transposition of great arteries
 ► Q234: Hypoplastic left heart
 ► Q35: Cleft palate
 ► Cleft lip with or without cleft palate
 – Q36: Cleft lip
 – Q37: Cleft palate with cleft lip
 ► Oesophageal atresia
 – Q390: Atresia of oesophagus without fistula
 – Q391: Atresia of oesophagus with trachea-oesophageal fistula
 ► Q790: Diaphraghmatic hernia
 ► Q793: Gastroschisis
 ► Q642: Posterior urethral valves
 ► Q660: Clubfoot/talipes equinovarus
 ► Q750: (Non-genetic) craniosynostosis
 ► Eye anomalies:
 – Q110: Cystic eyeball
 – Q111: Other anophthalmos
 – Q112: Microphthalmos
 – Q120: Congenital cataract
 – Q150: Congenital glaucoma
 ► Q53: Undescended testicle (Australian registers only)
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unique study number will be sent to the data custodians 
(Cerebral Palsy Alliance, The University of Sydney) using 
secure data transfer systems according to each region’s 
preferred method of data transfer.
The most comprehensive data set possible will be deter-
mined by negotiation with individual registers. Where 
registers are not able to provide all requested data, avail-
able data will be accepted. For example, where data are 
not available for the full range of requested birth years 
(1991–2009), any subset of birth years will be accepted.
To ensure harmonisation of variables and enable 
pooling of data between regions, registers will be asked to 
code their data using data coding guidelines which follow 
coding systems from SCPE, EUROCAT and ACPR where 
possible. Variables to be requested are listed in box 2, 
and specific data coding guidelines can be found online 
(supplementary material online).
Classification of conditions:
Cerebral palsy
Cases will be classified as pre/perinatal CP if the brain 
injury occurred during the prenatal/perinatal period 
(pregnancy and during the first 28 completed days after 
birth), or the timing of injury is unknown. While the 
maximum age of injury included as postneonatal CP 
varies between registers,19 a common definition must 
be used to compare data across registers. Cases will be 
defined as postneonatally acquired if the injury is known 
to have occurred after 28 days of life and before 2 years 
of age.1
Congenital anomalies
The study will use the detailed classification guidelines 
published by EUROCAT for coding congenital anoma-
lies using International Classification of Diseases (ICD), 
10th Revision- British Paediatric Association (BPA) 
codes. They include conversion for ICD-9-BPA codes.20 
A computer algorithm used by EUROCAT will be used 
to classify all anomalies in the pooled data set into aeti-
ological groups (chromosomal, genetic syndromes, tera-
togenic syndromes, isolated, multiple). This algorithm 
will require manual review of approximately 10% of the 
cases.21
Timing of brain injury
Timing of injury will be estimated or confirmed using 
an established neuroimaging classification of timing of 
insults leading to CP.22
Timing of congenital anomalies
Estimates of timing of congenital anomalies will be devel-
oped using descriptions of embryological development 
and congenital anomalies proposed by Czeizel.23
Quality assessment
The primary register will conduct a quality assurance 
assessment of three key data items provided by both the 
CP and congenital anomaly registers: birth weight, gesta-
tional age and plurality of birth. The primary register will 
determine, with negotiation with the secondary register 
where appropriate, the highest quality data for each item 
for cases. This data will be included in the final data sheet 
provided to the data custodians.
Congenital anomaly data on CP registers is expected to 
generally be of lower quality than on congenital anomaly 
registers.10 However, since anomaly registers may not 
include anomalies identified beyond a certain age, chil-
dren with later diagnosed anomalies may be only recorded 
on the CP register. Investigators from the Cerebral Palsy 
Alliance, The University of Sydney, will complete a manual 
quality assurance review for each case with CP. Where 
the congenital anomaly information provided by the CP 
and congenital anomaly registers differ, the individual 
case will be reviewed according to a designated process 
(figure 1) and a decision made regarding the congenital 
anomaly information to be included in the final data set.
Cleaned data from each region will be included in a 
new pooled database of anonymised data, and housed 
securely at the Cerebral Palsy Alliance, The University of 
Sydney, for data analysis.
statistical analysis
The expected sample size for this study (based on our 
previous survey and confirmation of participation forms 
returned from each register) is approximately 8500 cases 
box 2 Collected data items
data from cerebral palsy (CP) or congenital anomaly 
register
 ► Gestation age at delivery
 ► Birth weight
 ► Plurality of birth
 ► Cofetal loss
 ► Year of birth
 ► Living/deceased
 ► Age at death
 ► Sex
 ► Maternal age at delivery
data from CP register
 ► Postneonatal cause of CP
 ► CP subtype and topography
 ► Gross motor function classification system (GMFCS)30
 ► Intellectual impairment
 ► Visual impairment
 ► Hearing impairment
 ► Epilepsy
 ► Speech impairment
 ► Imaging results (neonatal and postneonatal)
 ► Associated syndromes
 ► Congenital anomalies (code and text)
data from congenital anomaly register
 ► Maternal illness before pregnancy
 ► Family history of congenital anomalies
 ► Congenital anomalies (code and text)
 ► Age at diagnosis
 ► Surgery performed for anomaly
 o
n
 26 July 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-022190 on 23 July 2018. Downloaded from 
6 Goldsmith S, et al. BMJ Open 2018;8:e022190. doi:10.1136/bmjopen-2018-022190
Open access 
of CP. Sample size calculations were completed using 
SPSS Sample Power 3 and show that our expected popu-
lation exceeds the sample size estimated to be required 
for our research questions. Specific examples follow:
 ► Research question a ‘what is the frequency and 
proportion of children with CP that have a congen-
ital anomaly?’ Given that approximately 5% of the 
general population have a congenital anomaly, at 90% 
power, a sample size of 13–90 cases of CP is required 
to detect a proportion of 15%–40% of CP cases having 
a congenital anomaly.
 ► Research question a stratified by GA ‘what is the 
frequency and proportion of children with CP that 
have a congenital anomaly, for term infants?’ 60% of 
children with CP are born at term, and the association 
with congenital anomalies is strongest in term infants. 
With 90% power, a sample size of 9–23 cases of CP 
is required to detect the proportion of term children 
with CP having a congenital anomaly.
 ► Research question c ‘what is the risk of CP for infants 
with specific congenital anomalies, for example holo-
prosencephaly?’ The least common targeted congen-
ital anomaly for these analyses is holoprosencephaly. 
Literature suggests that 0.18% of CP cases have holo-
prosencephaly10 while the general population esti-
mate is 0.24/10 000 live births. A sample size of 14 
cases with holoprosencephaly in the general popu-
lation is required to determine the risk of CP. We 
expect to have approximately 70 cases of this specific 
anomaly.
IBM SPSS V.24 will be used for statistical analysis for this 
research programme. After the data set from each region 
is received by the Cerebral Palsy Alliance, The Univer-
sity of Sydney, it will be analysed for missing data prior 
to pooling into one single file. Where a region has >20% 
of data missing for a variable, this variable will likely be 
excluded from that region’s final data set. However, if 
available data for that variable show the same trend as 
regions with minimal missing data, it may be included. 
This will be evaluated on a variable by variable basis. Data 
analyses will include: descriptive analyses of cerebral and 
non-cerebral anomalies found in CP; descriptive analyses 
of clinical outcomes (eg, type of CP, severity, additional 
non-motor impairments); descriptive analyses to compare 
timing of congenital anomaly and timing of brain injury/
abnormality responsible for CP; ORs (univariate and 
multivariate) to calculate the odds of CP associated with 
specific congenital anomalies.
Patient and public involvement
The development of this research study protocol was 
informed by the responses of people with CP and their 
families to our Delphi study regarding research priorities 
for CP.24 A parent representative reviewed and contrib-
uted to a funding application for the study. The study 
plan was reviewed and approved by a consumer advi-
sory committee from the Western Australian Register of 
Developmental Anomalies, which will contribute data to 
the study. Summaries of study results will be developed 
in consultation with consumer representatives from CP 
Quest25 and will be distributed through the newsletters of 
participating registers.
EthICs And dIssEMInAtIon
This overarching project has ethical approval. Further-
more, where an individual register deemed it necessary, 
additional ethical approval or permission to perform 
data linkages has been obtained. This study will result in 
the creation of a large data set, which will be used for 
Figure 1 Quality assurance flowchart for resolving discrepancies between cerebral palsy (CP) and congenital anomaly 
registers. ICD, International Classification of Diseases.
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multiple substudies addressing the listed research ques-
tions. We anticipate a range of publications and confer-
ence presentations will result from the study findings. 
Additionally, recommendations will be made regarding 
the collection and classification of congenital anomaly 
data by CP registers.
dIsCussIon
This epidemiological study will allow investigation of the 
co-occurrence of congenital anomalies and CP in the 
largest population-based sample to date. New knowledge 
will be generated about the specific anomalies found in 
CP and outcomes for these children, the risk of CP for 
those with specific anomalies, and the specific anomalies 
likely to be on causal pathways to CP. Furthermore, it will 
develop processes that can be used broadly in CP aeti-
ology research regarding the classification of both single 
and multiple congenital anomalies.
Variation between registers in inclusion/exclusion 
criteria, variables collected and their definitions can 
present a challenge for large collaborative studies. The 
strengths of our study are the use of strict definitions 
from established networks (eg, EUROCAT, SCPE and 
ACPR) and flexibility in which registers are included in 
individual analyses, which will help to maintain integrity. 
Another strength is the use of multiple population-based 
registers which help to minimise bias. Furthermore, by 
obtaining congenital anomaly data from both CP and 
congenital anomaly registers, we have the option of 
including the most comprehensive and highest quality 
description of prevalence of congenital anomalies. Finally, 
this will be the first study to report risk of CP for individ-
uals with the congenital anomalies most strongly associ-
ated with CP. We seek to build on previous research which 
reported an increased prevalence of CP for children with 
congenital anomalies in nervous, cardiovascular, respira-
tory and musculoskeletal systems.26 By identifying those 
specific anomalies with the greatest risk of CP, we seek to 
encourage clinicians and congenital anomaly researchers 
to be more aware of the potential for CP for these chil-
dren which may contribute to earlier detection and inter-
vention for CP and better family counselling.
A limitation of our study relates to the different ages 
when children are included on congenital anomaly and 
CP registers. CP registers require that a description and 
clinical presentation of CP is confirmed at age 4 or 5 years, 
whereas congenital anomalies registers tend to register at 
an earlier age. Children included in a congenital anom-
alies register may have migrated out of the region before 
registration on the equivalent CP register at age 4 or 5, 
leading to possible underestimation of cases with both CP 
and congenital anomalies. Migration has a greater impact 
for registries covering a small geographical region than 
those covering larger areas. The study is also limited by 
the inclusion only of regions in Europe and Australia. 
The epidemiology of both CP and congenital anom-
alies differs regionally,27 28 particularly between low/
middle-income and high-income countries. We will not 
be able to generalise these findings, especially to low-in-
come and middle-income countries.
We expect there to be substantial differences in the 
live birth prevalence of congenital anomalies between 
regions, due to differences in ascertainment, statistical 
uncertainty due to small numbers, prenatal screening 
and diagnostics and rates of terminations of pregnancy. 
Higher rates of terminations with severe, but not neces-
sarily lethal, anomalies could also be one of the factors 
explaining recently reported reductions in rates of CP in 
some populations.2 3
With this large, collaborative study, we hope to gain a 
comprehensive understanding about the group of chil-
dren with both CP and major congenital anomalies. 
Congenital anomalies are routinely listed as exclusion 
criteria for trials of neuroprotective treatments, yet the 
primary prevention of congenital anomalies is a focus 
of several groups worldwide.29 Improved understanding 
of the causes of co-occurring anomalies and CP is an 
important step towards identifying new primary preven-
tion strategies specifically for this group.
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